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E-mail: arecchia@unimore.itDespite advances in genome editing technol-
ogies based on the adeno-associated virus
(AAV)-CRISPR system, there are still con-
cerns about the long-term persistence of re-
combinant AAV vectors in several organs
(liver, muscle, eye) possibly leading to cyto-
toxicity or genotoxicity related to off-target
effects. Indeed, there are still unanswered
questions about long-lasting in vivo AAV
persistence as a linear or circular DNA that
is not targeted by epigenetic silencing in
many tissues. In 2017, Kim et al.1 reported
an editing approach based on AAV-CjCas9
to downregulateVegfa or the hypoxia-induc-
ible transcription factor Hif1a in mice dis-
playing age-related macular degeneration
(AMD)-related pathological choroidal neo-
vascularization (CNV) induced by laser
treatment. Although partial knockdown of
either Vegfa or Hif1a provided beneﬁts
and reduced the area of CNV, local opsin
dysfunction near the Vegfa-edited cells of
murine retinal pigment epithelium (RPE)
was observed. Conversely, no cone dysfunc-
tion was reported upon Hif1a partial knock-
down. Lastly, no genome-wide off-target
indels, evaluated 6 weeks after intravitrealinjection of AAV-CjCas9 vector, were
scored, indicating that prolonged expression
of AAV-CjCas9 in vivo did not aggravate
the genotoxic risk associated with the
CjCas9 nuclease. In this issue of Molecular
Therapy, the authors now report a long-
term (14 months) safety study on C57BL/6J
mice intravitreally injected with AAV-
CjCas9 vectors targeting Vegfa or Hif1a
genes.2 The ﬁndings continue to show that
the AAV-CRISPR system in the eyes is
long lasting, effective, and safe.
CRISPR/Cas9 genome editing in the retina
represents a potential treatment strategy for
inherited retinal dystrophies (e.g., autosomal
dominant retinitis pigmentosa [adRP] and
Leber congenital amaurosis [LCA]) and
retinal neovascular diseases (e.g., wet
AMD and proliferative diabetic retinop-
athy). CRISPR components have been deliv-
ered to the retina by viral and non-viral
methods. Although subretinal plasmid elec-
troporation is not suitable for therapeutic in-
terventions in patients, it has been employed
to knock down a mutant Rhodopsin gene in
mouse3 and rat4 models of adRP. Recently,preassembled Vegfa-speciﬁc Cas9 ribonu-
cleoproteins (RNPs) have been subretinally
injected into a mouse model of AMD,
demonstrating a signiﬁcant reduction of
laser-induced CNV. However, the effects
were localized only to the injected area of
RPE, with no transduction of the neural
retina.5
Nonvirally-mediated transient expression of
CRISPR components in the retina may
reduce safety concerns, although viral deliv-
ery systems based on AAV represent the
most efﬁcient and safe tools for gene delivery
to the retina. Indeed genome editing using
the AAV-CRISPR system has been widely re-
ported as efﬁcient, safe, and precise in more
than 30 published studies in mouse models6
of diseases associated with the eyes, muscle,
liver, heart, and lung. Despite the great po-
tential of AAV vectors, their relatively small
packaging capacity represents a limitation
for delivering the widely used Streptococcus
pyogenes Cas9 (SpCas9) together with guide
RNAs (gRNAs) and large transgenes. Dual-
vector AAV systems, smaller Cas9 orthologs,
or other nucleases belonging to the type-V
www.moleculartherapy.org
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have circumvented the transgene packaging
issue. Packaging of SpCas9 and gRNA into
two separate AAV particles proved to be a
successful delivery strategy.7 Similarly, an
AAV-split-Cas9 system has been developed.
These strategies rely on the possibility to re-
assemble the Cas9 holoenzyme in trans-
duced cells by fusing the N- and C-terminal
domains of Cas9 to Rapamycin-inducible
FRB-FKBP dimerization domains8 or Intein,
thus triggering trans-splicing of Intein-
tagged Cas9 domains.9 Smaller Cas9 ortho-
logs from Staphylococcus aureus (SaCas9),10
Campylobacter jejuni (CjCas9),1 Strepto-
coccus thermophilus (StCas9),11 and Neisse-
ria meningitidis (NmCas9)12 have also been
isolated. Owing to their smaller size (2.9–
3.3 kb) compared to SpCas9, they potentially
could be suitable for packaging into a single
AAV vector also bearing the gRNA. How-
ever, StCas9 and NmCas9 have been ne-
glected owing to their longer protospacer
adjacent motif (PAM), which represents a
limitation on sequences available for target-
ing. Conversely, SaCas9 and CjCas9 have
been successfully vectorized together with
gRNAs in a single AAV and show cutting
ability comparable to SpCas9 in in vitro
applications.5 More recently, Cpf1 nuclease
isolated from Lachnospiraceae bacterium
(LbCpf1) has been vectorized together with
the cognate CRISPR RNA (crRNA) into a
single AAV vector,13 demonstrating its great
potential as an in vivo genome editing tool
for the treatment of angiogenesis-related
diseases.
AAV-CRISPR systems based on CjCas9 and
LbCpcf1 nucleases have been developed to
treat AMD, and AAV-CRISPR persistence
and safety issues have been examined
in mice.14,15 Currently, patients with wet
AMD beneﬁt from intravitreal injection of
anti-vascular endothelial growth factor
(VEGF) agents (e.g., ranibizumab, bevacizu-
mab, and aﬂibercept). However, there is a
compelling need for a long-lasting therapy
solution for patients with AMD because of
the cost of the drugs, patient access to treat-
ment, and the increasing number of pa-
tients as the population ages. In the new
study, the authors showed no changes in
histologic integrity and function of retinaltissues treated with AAV-CjCas9.2 Then
they reported an efﬁcient editing in both
target genes 6 weeks post-injection, which
clearly increased 8 weeks later in both retina
and RPE, although Vegfa-speciﬁc indels
arose only in the retina. These data indicate
the long-term persistence of constitutively
expressed and active CjCas9 nuclease in
the injected area. Lastly, the authors
analyzed the potential off-target sites by tar-
geted deep sequencing and performed a
comprehensive genome-wide analysis of
potential off-targets sites bearing up to 4
nucleotide mismatches in the mouse
genome. Any detectable indels were scored
in 21 homologous sites. Altogether, this
study demonstrated that intravitreal injec-
tion of AAV-CjCas9 vector targeted to
Hif1a effectively induced and maintained
mutations in murine retinal cells for
14 months without giving rise to off-target
indels due to the constitutively active
CjCas9 nuclease and without affecting
retinal histologic integrity or function.
Unfortunately, no data on CNV ameliora-
tion 14 months post-injection are reported.
It would have been extremely useful to
see whether higher indel frequency at target
sites resulted in more effective treatment of
wet AMD.
Other AAV-CRISPR systems developed
for treatment of adRP or LCA 107,16–18
showed prolonged and safe expression (up
to 9.5 months) of subretinal-injected
AAV-SpCas9 targeting speciﬁc mutations
in RHO or CEP290 genes or targeting neural
retina leucine zipper transcription factor
(Nrl) in mouse models for adRP. Although,
in these studies, the authors employed
different AAV serotypes and different vector
doses and targeted different genes, the
results showed effective rescue of RP or
LCA 10 phenotype without toxicity or off-
target effects. We now have a potent molec-
ular tool to employ in several eye disorders
because Kim’s group demonstrated a robust
in vivo knock down of a murine transcrip-
tion factor, perfectly conserved in the human
genome and involved in tumor angiogenesis
and pathophysiology of ischemic disease,
and maybe this strategy could be translated
to other vascularization-associated human
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approach is the use of chimeric antigen recep-
tor (CAR) T cells. While adoptive transfer of
CAR T cells has seen striking results in some
malignancies, its efﬁciency has been tempered
in others due to limited expansion, persis-
tence, and tumor homing of the transferred
cells.1 Another clinical limitation is the serious
toxicities that may arise following CAR T cell
tumor recognition (reviewed in Sadelain
et al.2). This raises a very important issue
thatmust be resolved for proper cell engineer-
ing: are we fully harnessing the biology of arti-
ﬁcial T cell signaling for effective immuno-
therapy? A recent paper in Science Signaling
by Salter et al.3 demonstrates that the signaling
cascades initiated by synthetic CARs cannot
be predicted entirely by their design and sheds
light on the differences between the phos-
phorylation of the proteomes of CD28/CD3z
compared to 4-1BB/CD3z CAR T cells.
The last decade has seen the emergence of
antitumor therapeutic development. The
Nobel Prize in Physiology or Medicine
2018, awarded to James P. Allison and
Tasuku Honjo, has added to the enthusiasmtoward immunotherapy. Their work has
created a major shift in our understanding
of the immune system recognition of malig-
nancies and how we can manipulate this new
weapon to our advantage. We are indeed
entering a new era where immunotherapy
will soon complement standard radiotherapy
or chemotherapy regiments for cancer
treatment.
CAR T cells are engineered T cells expressing
fusion proteins, mostly combining an anti-
gen-speciﬁc single-chain fragment (scFv)
coming from a monoclonal antibody with
T cell receptor (TCR) intracellular signaling
domains. In vitro studies have demonstrated
that ﬁrst-generation CAR T cells, containing
only a CD3z moiety, support T cell activa-
tion and target cytotoxicity, but with very
limited persistence and antitumor efﬁcacy
following adoptive transfer.4 Second-genera-
tion CARs, therefore, incorporated a two-
signal model of T cell activation by modi-
fying the CARs to include a CD28 or
4-1BB (CD137) costimulatory domain that
provides signals for T cell effector function,
proliferation, and, more importantly, persis-tence.5,6 Nevertheless, in recent years, these
CAR constructs have shown variable effects
in vivo. Therefore, the authors of the new
study aimed to assess whether differences be-
tween CD28/CD3z and 4-1BB/CD3z CAR
T cells were attributable to divergent T cell
activation pathways. Human primary
T cells were transduced with modiﬁed lenti-
viral vectors encoding CD19- or ROR1-spe-
ciﬁc CD28/CD3z CARs and identical CD19-
or ROR1-speciﬁc 4-1BB/CD3z CARs fused
to a nine-amino acid Strep-tag II (STII)
sequence in the extracellular CAR hinge. Ca-
nonical T cell signaling events were then
evaluated following STII microbead stimula-
tion. Using an elegant phosphoproteomic
approach with liquid chromatography-
tandem mass spectrometry (LC-MS/MS),
they identifed many novel phosphoprotein
signaling events in stimulated CARs that
were not identiﬁed using previous methods.
Of note, both CD28/CD3z and 4-1BB/
CD3z CARs could promote phosphorylation
of endogenous CD28 following stimulation.
Surprisingly, they concluded that patterns
of protein phosphorylation were very similar
in cells expressing either of these CAR
